Cellules HepG2 : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules HepG2 : Questions médicales les plus fréquentes", "headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-11", "dateModified": "2025-02-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules HepG2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hépatocytes", "url": "https://questionsmedicales.fr/mesh/D022781", "about": { "@type": "MedicalCondition", "name": "Hépatocytes", "code": { "@type": "MedicalCode", "code": "D022781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436.348" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules HepG2", "alternateName": "Hep G2 Cells", "code": { "@type": "MedicalCode", "code": "D056945", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wilson de Melo Cruvinel", "url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com." } }, { "@type": "Person", "name": "Paulo Luiz Carvalho Francescantonio", "url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil." } }, { "@type": "Person", "name": "Alessandra Dellavance", "url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance", "affiliation": { "@type": "Organization", "name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil." } }, { "@type": "Person", "name": "Luis Eduardo Coelho Andrade", "url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade", "affiliation": { "@type": "Organization", "name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br." } }, { "@type": "Person", "name": "Antônio Carlos Ximenes", "url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes", "affiliation": { "@type": "Organization", "name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "HIV DNA positively correlates with HLA-DR+CD8+ T lymphocytes over 8-year suppressive antiretroviral therapy.", "datePublished": "2023-04-20", "url": "https://questionsmedicales.fr/article/37115824", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/QAD.0000000000003587" } }, { "@type": "ScholarlyArticle", "name": "RASAL3 predicts overall survival and CD8+ T lymphocyte infiltration in lung adenocarcinoma.", "datePublished": "2022-11-24", "url": "https://questionsmedicales.fr/article/36420686", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jcmm.17625" } }, { "@type": "ScholarlyArticle", "name": "High density of CD8 T cell and immune imbalance of T lymphocytes subsets are associated with proliferative verrucous leukoplakia.", "datePublished": "2022-09-03", "url": "https://questionsmedicales.fr/article/36056642", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/imm.13565" } }, { "@type": "ScholarlyArticle", "name": "CD8 T", "datePublished": "2023-12-01", "url": "https://questionsmedicales.fr/article/38039378", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1126/sciimmunol.adn0644" } }, { "@type": "ScholarlyArticle", "name": "High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma.", "datePublished": "2024-09-05", "url": "https://questionsmedicales.fr/article/39235606", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-024-03799-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Hépatocytes", "item": "https://questionsmedicales.fr/mesh/D022781" }, { "@type": "ListItem", "position": 5, "name": "Cellules HepG2", "item": "https://questionsmedicales.fr/mesh/D056945" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules HepG2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules HepG2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules HepG2", "description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules HepG2", "description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules HepG2", "description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules HepG2", "description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules HepG2", "description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules HepG2", "description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=CD8-Positive+T-Lymphocytes#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules HepG2 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les HepG2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules HepG2 présentent-elles des symptômes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux cellules HepG2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques." } }, { "@type": "Question", "name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques." } }, { "@type": "Question", "name": "Comment les HepG2 contribuent-elles à la recherche préventive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique." } }, { "@type": "Question", "name": "Peut-on utiliser HepG2 pour tester des médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments." } }, { "@type": "Question", "name": "Comment les HepG2 aident-elles à développer des traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec HepG2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées." } }, { "@type": "Question", "name": "Les HepG2 aident-elles à comprendre les complications du foie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec HepG2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés." } }, { "@type": "Question", "name": "Comment HepG2 aide à identifier des facteurs de risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques." } } ] } ] }